OBJECTIVES: Determine local current clinical practice for C. difficile infection (CDI) in Mexico, including what are the most prevalent methods of diagnosis and what is the most common threshold between treating empirically and following response vs. testing for primary and recurrent CDI, frequency of metronidazole and vancomycin use, in what patient types and rates of empirical use before definitive diagnosis for each group (primary, recurrent, elderly, immunocompromised, etc.) and Use of resources associated with diagnosis and treatment for patients treated at home and in the hospital for primary and recurrent CDI. METHODS: Delphi technique in a population of 7 infectologist and 3 gastroenterologists, 2 iterations were held online through monkeysurvey© and questions about diagnosis, treatment and incidence were asked gathering information for three groups: immunocompromised, immunocompetent or older than 65 years. Al panelists work in government institutions. Descriptive statistics was performed to describe the results of the panel. RESULTS: The minimum requierements for diagnosing CDI in immunocompetent patients according to the expert´s opinion are a medical consultation (specialty consultation or ER) and EIA/ELISA test. in Mexican government institutions, an estimate of 52% of the primary infections are mild to modereate, 32% are severe and only 16% are very severe or complicated independently of the population group. 50% of the patients with a primary infection are treated empirically and only 40% are treated as outpatient. in the recurrent patients, 90% are treated empiracally and 20.5% are treated as outpatients. CONCLUSIONS: Incidence on primary and recurrent CDI in Mexico do not vary much from the reported worldwide. Treating empiracaly is mainly based on severity of the disease and to avoid horizontal transmission. Even though the majority of patients present with mild to modereate infection, intrahospitalary treatment is preferred over outpatient treatment. Outpatient management decreases dramatically when a recurrent infection ocurrs. This could increase costs of treatment seriously.